Compounds and methods for treatment and diagnosis of...

Details Compounds and methods for treatment and diagnosis of... Compounds and methods for treatment and diagnosis of...

2004-06-18

2008-12-09

Minnifield, N. M (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S184100, C424S190100, C424S234100, C424S192100, C424S200100, C424S185100, C530S350000, C514S002600, C514S008100

Reexamination Certificate

active

07462357

ABSTRACT:
Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of aChlamydiaantigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

REFERENCES:
patent: 4118469 (1978-10-01), Caldwell et al.
patent: 4497900 (1985-02-01), Armstrong et al.
patent: 5166053 (1992-11-01), Huguenel et al.
patent: 5318892 (1994-06-01), Watanabe et al.
patent: 5725863 (1998-03-01), Daniels et al.
patent: 6166177 (2000-12-01), Probst et al.
patent: 6432916 (2002-08-01), Probst et al.
patent: 6447779 (2002-09-01), Probst et al.
patent: 6448234 (2002-09-01), Fling
patent: 6555115 (2003-04-01), Probst et al.
patent: 6565856 (2003-05-01), Skeiky et al.
patent: 6899880 (2005-05-01), Stephens et al.
patent: 6919187 (2005-07-01), Bhatia et al.
patent: 7041490 (2006-05-01), Griffais et al.
patent: 7101963 (2006-09-01), Griffais et al.
patent: 7105171 (2006-09-01), Stephens et al.
patent: 7253275 (2007-08-01), Stephens et al.
patent: 7361353 (2008-04-01), Grandi et al.
patent: 7384638 (2008-06-01), Bhatia et al.
patent: 2002/0062848 (2002-05-01), Luscher et al.
patent: 2004/0029129 (2004-02-01), Wang et al.
patent: 2004/0131625 (2004-07-01), Berthet et al.
patent: 2004/0234536 (2004-11-01), Bhatia et al.
patent: 2005/0106162 (2005-05-01), Grandi et al.
patent: 2005/0239160 (2005-10-01), Shaw et al.
patent: 2005/0281847 (2005-12-01), Berthet et al.
patent: 2006/0034871 (2006-02-01), Grandi et al.
patent: 2008/0124338 (2008-05-01), Li et al.
patent: 348725 (1990-01-01), None
patent: 784 059 (1997-07-01), None
patent: WO 94/06827 (1994-03-01), None
patent: WO 97/06263 (1997-02-01), None
patent: WO 98/02546 (1998-01-01), None
patent: WO 98/10789 (1998-03-01), None
patent: WO 99/17741 (1999-04-01), None
patent: WO 99/27105 (1999-06-01), None
patent: WO 99/28475 (1999-06-01), None
patent: WO 99/51748 (1999-10-01), None
patent: WO 00/34483 (2000-06-01), None
patent: WO 00/34483 (2000-06-01), None
patent: WO 01/40474 (2001-06-01), None
patent: WO 02/08627 (2002-01-01), None
patent: WO 02/062380 (2002-08-01), None
patent: WO 02/077183 (2002-10-01), None
patent: WO 03/049762 (2003-06-01), None
patent: WO 2005/002619 (2005-01-01), None
patent: WO 2005/106162 (2005-11-01), None
Bixler et al, In: Synthetic Vaccines, editor Ruth Arnon, 1987, pp. 39-71.
Burgess et al, JCB, 1990, 111:2129-2138.
Houghten et al, In: Vaccines86, editor Brown et al, 1986, pp. 21-25.
Bowie et al, Science, Mar. 16, 1990,247:1306-1310.
Kumar et al, PNAS USA, Feb. 1990, 87:1337-1341.
Lazar et al, Molecular and Cellular Biology, Mar. 1988, 8:1247-1252.
Pannekoek et al, Drugs of Today, 2006, 42/Suppl. A:65-73.
Schnorr, JAVMA, Dec. 1, 1989, 195/11:1548-1561.
Creighton, In: Proteins, 1984, pp. 314-315.
Creighton, In: Protein Structure a practical approach, 1989, pp. 184-186.
Brunham et al, Infectious Agents and Disease, 1994, 3:218-233.
Mygind et al, FEMS Microbiology Letters, 2000, 186:163-169.
Baehr et al, PNAS, 1988, 85:4000-4004.
Batteiger, Infection and Immunity, 1996, 62/2:542-547.
Igietseme et al, Infection and Immunity, 2000, 68/12:6798-6806.
Gervassi et al, J. Immunology, 2004, 173:6905-6913.
Hickey et al, Current Molecular Medicine, 2005, 5:599-605.
Fling et al, PNAS, 2001, 98/3:1160-1165.
Goh et al, Sexually Transmitted Infections, Jun. 1, 2006, 82/3:219-220 abstract only.
Jen et al, ASM 101stGeneral Meeting, May 22, 2001, p. E-70 meeting abstract.
Stagg, Molecular Medicine Today, Apr. 1998, pp. 166-173.
Maclean et al, can. J. Microbiol, 1988, 34:141-147.
Pal et al, Infection and Immunity, Aug. 1997, 65/8:3361-3369.
Stephens et al, Science, Oct. 23, 1998, 282:754-759.
Nosoh et al, Protein Stability and Stabilization Through Protein Engineering, 1991, pp. 197-217.
Su et al, Vaccine, 1995, 13/11:1023-1032.
Campos et al, Invest. Ophthalmol. Vis. Sci., Jul. 1995, 36/8:1477-1491 abstract only.
Baehr et al., “Mapping antigenic domains expressed byChlamydia trachomatismajor outer membrane protein genes,”Proc Natl Acad Sci 85(1):4000-4004, Jun. 1, 1988.
Brunham et al., “Chlamydia trachomatisantigens: role in immunity and pathogenesis,”Infectious Agents and Disease 3(5):218-233, Oct. 1994.
Kim, S.-K. et al., “Induction of HLA Class I-Restricted CD8+CTLs Specific for the Major Outer Membrane Protein ofChlamydia trachomatisin Human Genital Tract Infections,”The Journal of Immunology 162: 6855-6866, 1999.
Maclean, I.W. et al., “Characterization ofChlamydia trachomatisantigens with monoclonal and polyclonal antibodies,”Can. J. Microbiol. 34: 141-147, 1988.
Mygind, P.H. et al., “Membrane proteins PmpG and PmpH are major constituents ofChlamydia trachomatisL2 outer membrane complex,”FEMS Microbiol. Lett. 186(2): 163-169, May 15, 2000.
Pal, S. et al., “Immunization with an Acellular Vaccine Consisting of the Outer Membrane ofChlamydia trachomatisInduces Protection against a Genital Challenge,”Infection and Immunity 65(8): 3361-3369, Aug. 1997.
Stagg, A.J. et al., “Vaccines againstChlamydia: approaches and progress,”Molecular Medicine Today 4(4): 166-173, Apr. 1998.
Stephens et al., “Genome Sequence of an Obligate Intracellular Pathogen of Humans:Chlamydia trachomatis,” Science 282:754-759, 1998.
Su, H. et al., “Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model ofChlamydia trachomatisgenital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection,”Vaccine 13(11): 1023-1032, 1995.
GenBank Accession No. AE001324, “Genome sequence of an obligate intracellular pathogen of humans:Chlamydia trachomatis,” Oct. 30, 1999.
Genbank Accession No. AE001326, Oct. 30, 2000.
GenBank Accession No. AE001335, “Genome sequence of an obligate intracellular pathogen of humans:Chlamydia trachomatis,” Oct. 30, 1999.
Genbank Accession No. AE001361, Jul. 22, 1998.
GenBank Accession No. E71500, “Genome sequence of an obligate intracellular pathogen of humans:Chlamydia trachomatis,” Oct. 8, 1999.
GenBank Accession No. H71501, “Genome sequence of an obligate intracellular pathogen of humans:Chlamydia trachomatis,” Oct. 8, 1999.
GenBank Accession No. H71510, “Genome sequence of an obligate intracellular pathogen of humans:Chlamydia trachomatis,” Oct. 8, 1999.
GenBank Database, Accession No. NC—000117, Dec. 9, 2002.
Grimwood, J. et al., “Expression ofChlamydia pneumoniaePolymorphic Membrane Protein Family Genes,”Infection and Immunity 69(4): 2383-2389, Apr. 2001.
Gu et al., “Chlamydia trachomatisRNA polymerase α subunit: sequence and structural analysis,”J. Bacteriology 177:2594-2601, May 1995.

Affiliated with

Also associated with

Rating

Compounds and methods for treatment and diagnosis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds and methods for treatment and diagnosis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for treatment and diagnosis of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4036243